Gapping down
In reaction to earnings/guidance:
- FOR -10%, BBWI -8.6%, BKR -4.7%, IBKR -2.2%, JBHT -2%, HOPE -1%, BIIB -1%, ASML -0.9%, ELV -0.7%
Other news:
- VBLT -77.1% (announces top-line data from OVAL Trial)
- RVMD -11.5% (prices offering of 11.5 mln shares of common stock at $20.00 per share)
- INZY -4.8% (announces preliminary data from Phase 1/2 trial of INZ-701)
- OMIC -3.4% (files for $250 mln mixed securities shelf offering)
- GOGL -3% (files mixed securities shelf offering)
- LQDA -2.4% (US patent office rules in its favor)
- QGEN -1% (surpasses 3 mln NGS patient test cases)
- AIR -1% (awarded a Captains of Industry contract with the Defense Logistics Agency)
- MRK -0.9% (reports Phase 3 KEYNOTE-412 Trial did not meet its primary endpoint)
Analyst comments:
- ATRA -4.4% (downgraded to Sell from Neutral at Citigroup)
- ANET -3.9% (downgraded to Underperform from Buy at BofA Securities)
- FFIV -2.1% (downgraded to Neutral from Buy at BofA Securities)
- CMI -1.1% (downgraded to Mkt Perform from Outperform at Bernstein)
- EXLS -1.1% (downgraded to Sell from Neutral at Citigroup)
- EQR -1% (downgraded to Underweight from Neutral at Piper Sandler)
- ALLY -0.9% (downgraded to In-line from Outperform at Evercore ISI)